Home
   Links
   Faculty Information
   Activities & Events
   Melanoma Care Centers
 
   Slide Library
   Polling Results
   Patient Resources
 
   Contact Us
   Register
   Log-in
   
 
 
 
 
 
 
 
 
 

Although this activity is no longer certified for credit, we believe that it contains important information and hope you'll review, print or email it to a colleague.


Accreditation extended through June 2008
Melanoma Care Options™ Issue 1: Primary Disease

A case-based discussion of strategies for managing primary melanoma.

Authors: James M. Grichnik, MD, PhD
David E. Elder, MB, ChB, FRCPA
David R. Byrd, MD
John M. Kirkwood, MD
Merrick I. Ross, MD, FACS

1. Interested in reading the publication and earning CME credits on-line? Click here to register, download the publication and take the CME test and evaluation on line.

2. Just want to download the publication? Click here to download the publication. You can always print out and fax the CME information to us later.

Continuing Medical Education Information

Instructions for participation:

  • Read the case presentations and comments in the newsletter
  • Complete the posttest questions and evaluation form at the end of the newsletter, and fax or mail them to our office

To receive up to 1.5 AMA PRA category 1 credits for this activity:

  • 70% of your posttest answers must be correct for you to receive a certificate of credit To receive up to 1.8 CNE credits for this activity:
  • Within 4 weeks of successful completion, a certificate will be mailed to the address provided
  • 70% of your posttest answers must be correct for you to receive a certificate of credit

Target Audience

This activity is directed toward dermatologists, dermatologic surgeons, surgical and medical oncologists, general surgeons, oncology nurses, primary care physicians, and other health care professionals who treat or screen for melanoma.

Statement of Need

Primary melanomas are defined as the mass of cells confined to the original site of tumor development. In the absence of clinically evident regional or distant metastatic disease, they are classified as either stage I or stage II melanomas by the American Joint Committee on Cancer (AJCC) staging system. The prognosis for stage I or II patients is generally good if the disease is correctly treated. Therefore, clinicians should be familiar with the appropriate management of primary melanomas to maximize the chance for a cure. This publication describes in detail the management of primary melanomas and highlights important controversies that arise when caring for these patients.

Learning Objectives

After completing this activity, the participants will be able to

  • Outline the appropriate management strategies for patients presenting with atypical nevi
  • Compare and contrast types of biopsy and describe when each should be used
  • Describe the appropriate use of surveillance radiographs and blood tests in patients with early melanoma
  • Formulate a pathology report containing the necessary information to allow an informed treatment decision to be made
  • Offer appropriate recommendations for excision margins of the primary site based on microstaging information
  • Discuss the role of SLN biopsy in localized melanomas
  • Explain the rationale for tumor cutoff points for performing SLN biopsy

    Continuing Education Credit

    The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Pittsburgh School of Medicine designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Each physician should only claim credit commensurate with the extent of their participation in the activity.

    1.8 contact hours of Continuing Nursing Education will be granted by the University of Pittsburgh School of Nursing. The University of Pittsburgh School of Nursing is an approved provider of continuing nursing education by the Pennsylvania State Nurses Association (PSNA), an accredited approver by the American Nurses Credentialing Center�s Commission on Accreditation.

    We gratefully acknowledge an educational grant from Schering-Plough Corporation in support of this activity.

    Contributing Authors and Disclosure

    David R. Byrd, MD
    Professor of Surgery
    Department of Surgery
    University of Washington Medical Center
    Seattle, Washington
    Dr Byrd reports no financial interests to disclose.

    David E. Elder, MB, ChB, FRCPA
    Professor of Pathology
    Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania
    Dr Elder reports no financial interests to disclose.

    James M. Grichnik, MD, PhD
    Associate Professor
    Duke University Medical Center
    Durham, North Carolina
    Dr Grichnik discloses the following financial interests: Founder and Major Shareholder: DigitalDerm, Inc; Consultant/Grants: Electro-Optical Systems Inc.

    John M. Kirkwood, MD
    Director, Melanoma and Skin Cancer Program
    University of Pittsburgh Cancer Institute
    Professor and Vice Chairman for Clinical Research
    Department of Medicine
    Hillman Cancer Center
    Pittsburgh, Pennsylvania
    Dr Kirkwood discloses the following financial interests: Grants/Research Support: Schering-Plough Corporation, Berlex Laboratories, Pfizer Inc; Consultant: Antigenics Inc, MedImmune, Inc; Speakers� Bureau: Schering-Plough Corporation.

    Merrick I. Ross, MD, FA C S
    Professor of Surgical Oncology
    University of Texas M. D. Anderson Cancer Center
    Houston, Texas
    Dr Ross discloses the following financial interests: Speakers� Bureaus: Schering-Plough Corporation, Genentech, Inc.

    Date of Original Release: August 1, 2006
    Expiration Date: August 1, 2007
    Date of last review: August 1, 2006